Beyond aspirin: how glycoprotein inhibitors ease acute coronary syndromes.
MacCallum
E M
EM
Division of Cardiology, Presbyterian Medical Center, University of Pennsylvania Health System, Philadelphia, USA.
Hanlon
S J
SJ
Byrne
K H
KH
D000077284:Abciximab; D000208:Acute Disease; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy* / Q000451:nursing; D016903:Drug Monitoring; D000077542:Eptifibatide; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D009730:Nursing Assessment / Q000379:methods; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban; D000077542:Eptifibatide; D000077284:Abciximab